Table 2 Clinical–pathological characteristics of MED cohort
|  | ALL (n = 52) | pN0 (n = 10) | pN2 (n = 32) | pN1 (n = 10) |
|---|---|---|---|---|
Age | ||||
 Median (Q1;Q3) | 62.12 (59.18; 68.24) | 62.05 (59.81; 70.32) | 61.32 (58.82; 66.97) | 62.95 (59.86; 66.32) |
Gender | ||||
 Female | 15 (28.8%) | 3 (30%) | 9 (28.1%) | 3 (30%) |
 Male | 37 (71.2%) | 7 (70%) | 23 (71.9%) | 7 (70%) |
Histology | ||||
 LUAD | 30 (57.7%) | 4 (40%) | 22 (68.7%) | 4 (40%) |
 LUSC | 19 (36.5%) | 4 (40%) | 9 (28.1%) | 6 (60%) |
 NSCLC | 3 (5.8%) | 2 (20%) | 1 (3.1%) | 0 (0%) |
Stage | ||||
 IIIA | 46 (88.5%) | 8 (80%) | 29 (90.6%) | 9 (90%) |
 IIIB | 6 (11.5%) | 2 (20%) | 3 (9.4%) | 1 (10%) |
NACT regimen | ||||
 CDDP + ALIMTA | 6 (11.5%) | 0 (0%) | 5 (15.6%) | 1 (10%) |
 CDDP + GEM | 41 (78.8%) | 9 (90%) | 25 (78.1%) | 7 (70%) |
 CDDP + TAXOTERE | 1 (1.9%) | 0 (0%) | 1 (3.1%) | 0 (0%) |
 CDDP + VNR | 4 (7.7%) | 1 (10%) | 0 (0%) | 2 (20%) |
 VNR + GEM | 1 (1.9) | 0 (0%) | 1 (3.1%) | 0 (0%) |
Number of NACT cycles | ||||
 2–3 cycles | 42 (80.8%) | 9 (90%) | 24 (75%) | 9 (90%) |
 4–5 cycles | 9 (17.3%) | 1 (10%) | 7 (25%) | 1 (10%) |